JP2020536532A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536532A5 JP2020536532A5 JP2020518649A JP2020518649A JP2020536532A5 JP 2020536532 A5 JP2020536532 A5 JP 2020536532A5 JP 2020518649 A JP2020518649 A JP 2020518649A JP 2020518649 A JP2020518649 A JP 2020518649A JP 2020536532 A5 JP2020536532 A5 JP 2020536532A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- heavy chain
- seq
- amyloidosis
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010071690 Prealbumin Proteins 0.000 claims 11
- 102000009190 Transthyretin Human genes 0.000 claims 11
- 206010002022 amyloidosis Diseases 0.000 claims 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 claims 5
- 150000001413 amino acids Chemical class 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 201000007905 transthyretin amyloidosis Diseases 0.000 claims 4
- 206010007509 Cardiac amyloidosis Diseases 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 101000772194 Homo sapiens Transthyretin Proteins 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 102000056556 human TTR Human genes 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 208000027121 wild type ATTR amyloidosis Diseases 0.000 claims 2
- 230000007082 Aβ accumulation Effects 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 102000009490 IgG Receptors Human genes 0.000 claims 1
- 108010073807 IgG Receptors Proteins 0.000 claims 1
- 208000019428 Ligament disease Diseases 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000023835 Tendon disease Diseases 0.000 claims 1
- 210000000579 abdominal fat Anatomy 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 210000003403 autonomic nervous system Anatomy 0.000 claims 1
- 210000005252 bulbus oculi Anatomy 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000003041 ligament Anatomy 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000001428 peripheral nervous system Anatomy 0.000 claims 1
- 208000022256 primary systemic amyloidosis Diseases 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762569436P | 2017-10-06 | 2017-10-06 | |
| US62/569,436 | 2017-10-06 | ||
| US201762598965P | 2017-12-14 | 2017-12-14 | |
| US62/598,965 | 2017-12-14 | ||
| PCT/US2018/054720 WO2019071205A1 (en) | 2017-10-06 | 2018-10-05 | ANTI-TRANSTHYRETIN ANTIBODY |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020536532A JP2020536532A (ja) | 2020-12-17 |
| JP2020536532A5 true JP2020536532A5 (https=) | 2021-11-11 |
| JP7357609B2 JP7357609B2 (ja) | 2023-10-06 |
Family
ID=65994817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020518649A Active JP7357609B2 (ja) | 2017-10-06 | 2018-10-05 | 抗トランスサイレチン抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11267877B2 (https=) |
| EP (1) | EP3691447A4 (https=) |
| JP (1) | JP7357609B2 (https=) |
| KR (1) | KR20200074956A (https=) |
| CN (1) | CN111315213B (https=) |
| AU (1) | AU2018345806A1 (https=) |
| BR (1) | BR112020006434A2 (https=) |
| CA (1) | CA3077361A1 (https=) |
| CU (1) | CU24731B1 (https=) |
| MX (1) | MX2020003041A (https=) |
| PE (1) | PE20210552A1 (https=) |
| SA (1) | SA520411703B1 (https=) |
| SG (1) | SG11202002489YA (https=) |
| WO (1) | WO2019071205A1 (https=) |
| ZA (1) | ZA202002141B (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| CU24731B1 (es) | 2017-10-06 | 2025-01-15 | Prothena Biosciences Ltd | Anticuerpos anti-transtiretina |
| AU2018345807B2 (en) | 2017-10-06 | 2025-02-06 | Novo Nordisk A/S | Methods of detecting transthyretin |
| PE20211453A1 (es) | 2017-11-29 | 2021-08-05 | Prothena Biosciences Ltd | Formulacion liofilizada de un anticuerpo monoclonal contra transtirretina |
| MX2022014223A (es) * | 2020-05-12 | 2023-04-14 | Neurimmune Ag | Terapia de combinacion para amiloidosis de la ttr. |
| US20220267450A1 (en) | 2020-10-14 | 2022-08-25 | Viridian Therapeutics, Inc. | Compositions and methods for treatment of thyroid eye disease |
| CN116635024A (zh) * | 2020-10-14 | 2023-08-22 | 维里迪安治疗公司 | 用于治疗甲状腺眼病的组合物和方法 |
| WO2022155608A2 (en) * | 2021-01-15 | 2022-07-21 | The General Hospital Corporation | Cd64 chimeric receptor and uses thereof |
| EP4286406A4 (en) | 2021-01-29 | 2025-07-23 | Illimis Therapeutics Inc | FUSION MOLECULE WITH NON-INFLAMMATORY PHAGOCYTOSIS-INDUCING ACTIVITY |
| WO2023099788A1 (en) | 2021-12-03 | 2023-06-08 | Neurimmune Ag | Novel potency assay for antibody-based drugs and useful means therefor |
| CA3247456A1 (en) * | 2022-04-20 | 2023-10-26 | Senti Biosciences, Inc. | DOMAINS OF BINDING TO AN ANTIGEN AND THEIR METHODS OF USE |
| EP4630812A1 (en) | 2022-12-05 | 2025-10-15 | Neurimmune AG | Cyclic compounds and their use in assays for detecting antibodies |
| EP4713354A1 (en) | 2023-05-19 | 2026-03-25 | Neurimmune AG | Novel immunotherapy for musculoskeletal disorders and conditions |
| WO2024251997A1 (en) | 2023-06-07 | 2024-12-12 | Neurimmune Ag | Vaccine for the treatment of amyloidosis |
| EP4727650A1 (en) * | 2023-06-14 | 2026-04-22 | Immutrin Ltd | Anti-fibril antibodies |
| WO2025228442A1 (zh) * | 2024-04-30 | 2025-11-06 | 厦门大学 | 氯苯唑酸在激活rxr活性中的用途 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| AU2001253158A1 (en) | 2000-04-05 | 2001-10-23 | University Of Tennessee Research Corporation | Methods of investigating, diagnosing, and treating amyloidosis |
| ATE506072T1 (de) | 2002-09-12 | 2011-05-15 | Univ California | Immunogene und entsprechende antikörper, die spezifisch sind für häufige hochmolekulare aggregations-zwischenprodukte von amyloiden aus proteinen unterschiedlicher sequenz |
| WO2010012004A2 (en) | 2008-07-25 | 2010-01-28 | The Regents Of The University Of California | Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence |
| US20110200609A1 (en) | 2002-09-12 | 2011-08-18 | The Regents Of The University Of California | Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence |
| WO2005025516A2 (en) | 2003-09-12 | 2005-03-24 | The Regents Of The University Of California | Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates |
| WO2010011999A2 (en) | 2008-07-25 | 2010-01-28 | The Regents Of The University Of California | Methods and compositions for eliciting an amyloid-selective immune response |
| CA2604423A1 (en) * | 2005-04-13 | 2006-10-19 | Garvan Institute Of Medical Research | Modified animal lacking functional pyy gene, monoclonal antibodies that bind pyy isoforms and uses therefor |
| US7977314B2 (en) | 2005-12-02 | 2011-07-12 | Amorfix Life Sciences Limited | Methods and compositions to treat and detect misfolded-SOD1 mediated diseases |
| WO2008005455A2 (en) | 2006-07-03 | 2008-01-10 | The Johns Hopkins University | Peptide antibody depletion and its application to mass spectrometry sample preparation |
| EP2548647B1 (en) | 2006-10-20 | 2018-08-15 | CLONDIAG GmbH | Assay devices and methods for the detection of analytes |
| WO2010030203A1 (en) | 2008-09-09 | 2010-03-18 | Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. | Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr |
| AU2009301580B2 (en) | 2008-10-06 | 2015-11-26 | The University Of British Columbia | Methods and systems for predicting misfolded protein epitopes |
| JP2010195710A (ja) | 2009-02-25 | 2010-09-09 | Kumamoto Univ | アミロイド線維形成抑制剤及びその利用 |
| CA2753621A1 (en) | 2009-03-02 | 2010-09-10 | The University Of British Columbia | Antibodies and epitopes specific to misfolded prion protein |
| TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體 |
| FI20115165A0 (fi) | 2011-02-21 | 2011-02-21 | Polysackaridforskning I Uppsala Ab | Terapeuttisia ja diagnostisia menetelmiä |
| MX352889B (es) | 2011-02-25 | 2017-12-13 | Chugai Pharmaceutical Co Ltd | Anticuerpo de fc especifico para fcyriib. |
| AU2012233313C1 (en) | 2011-03-30 | 2017-08-03 | Chugai Seiyaku Kabushiki Kaisha | Method for altering plasma retention and immunogenicity of antigen-binding molecule |
| TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子 |
| EP2857419B1 (en) | 2012-05-30 | 2021-01-13 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule for eliminating aggregated antigens |
| US9534048B2 (en) * | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US9790269B2 (en) | 2013-02-08 | 2017-10-17 | Misfolding Diagnostics, Inc. | Transthyretin antibodies and uses thereof |
| WO2014142334A1 (ja) * | 2013-03-12 | 2014-09-18 | 国立大学法人名古屋大学 | 植物の光合成および生産量を増加させる方法 |
| EP3022225B1 (en) | 2013-07-19 | 2021-09-29 | Board Of Regents Of the University Of Texas System | Transthyretin amyloid-selective and polyreactive catabodies |
| KR20250057056A (ko) | 2013-12-20 | 2025-04-28 | 뉴리뮨 홀딩 아게 | 트랜스티레틴(ttr) 아밀로이드증의 항체-기반의 치료 및 이를 위한 인간-유래의 항체 |
| CN106459956B (zh) | 2014-01-29 | 2019-12-17 | 一般财团法人化学及血清疗法研究所 | 抗-运甲状腺素蛋白人抗体 |
| KR102538555B1 (ko) | 2014-01-29 | 2023-05-30 | 케이엠 바이올로직스 가부시키가이샤 | 항-트랜스티레틴 인간화 항체 |
| CN113599539A (zh) | 2014-08-29 | 2021-11-05 | 阿尔尼拉姆医药品有限公司 | 治疗甲状腺素运载蛋白（ttr）介导的淀粉样变性的方法 |
| TWI806150B (zh) | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| TWI718121B (zh) | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| TWI769570B (zh) | 2015-01-28 | 2022-07-01 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| TWI786505B (zh) | 2015-01-28 | 2022-12-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| WO2018007924A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| JP7016470B2 (ja) | 2016-07-02 | 2022-02-07 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
| WO2018007922A2 (en) | 2016-07-02 | 2018-01-11 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| AU2018345807B2 (en) | 2017-10-06 | 2025-02-06 | Novo Nordisk A/S | Methods of detecting transthyretin |
| CU24731B1 (es) | 2017-10-06 | 2025-01-15 | Prothena Biosciences Ltd | Anticuerpos anti-transtiretina |
| PE20211453A1 (es) | 2017-11-29 | 2021-08-05 | Prothena Biosciences Ltd | Formulacion liofilizada de un anticuerpo monoclonal contra transtirretina |
| WO2021168156A1 (en) | 2020-02-20 | 2021-08-26 | Prothena Biosciences Limited | Monitoring transthyretin amyloidosis |
-
2018
- 2018-10-05 CU CU2020000021A patent/CU24731B1/es unknown
- 2018-10-05 MX MX2020003041A patent/MX2020003041A/es unknown
- 2018-10-05 SG SG11202002489YA patent/SG11202002489YA/en unknown
- 2018-10-05 PE PE2020000481A patent/PE20210552A1/es unknown
- 2018-10-05 EP EP18863984.3A patent/EP3691447A4/en active Pending
- 2018-10-05 AU AU2018345806A patent/AU2018345806A1/en not_active Abandoned
- 2018-10-05 US US16/753,307 patent/US11267877B2/en active Active
- 2018-10-05 CN CN201880071788.1A patent/CN111315213B/zh active Active
- 2018-10-05 KR KR1020207012722A patent/KR20200074956A/ko not_active Ceased
- 2018-10-05 BR BR112020006434-3A patent/BR112020006434A2/pt unknown
- 2018-10-05 JP JP2020518649A patent/JP7357609B2/ja active Active
- 2018-10-05 CA CA3077361A patent/CA3077361A1/en active Pending
- 2018-10-05 WO PCT/US2018/054720 patent/WO2019071205A1/en not_active Ceased
-
2020
- 2020-04-05 SA SA520411703A patent/SA520411703B1/ar unknown
- 2020-05-04 ZA ZA2020/02141A patent/ZA202002141B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536532A5 (https=) | ||
| JP7254699B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| RU2007139953A (ru) | Антитела к ccr5 и их применение | |
| JP2018510617A5 (https=) | ||
| JP2020195382A (ja) | α−シヌクレインを認識する抗体を含む血液脳関門シャトル | |
| JP2020508655A5 (https=) | ||
| JP2019530427A5 (https=) | ||
| JP2020514277A5 (https=) | ||
| JP2010526028A5 (https=) | ||
| JP2018506277A5 (https=) | ||
| JP2017052784A5 (https=) | ||
| RU2009128064A (ru) | Антитела к cd44 | |
| JP2017526370A5 (https=) | ||
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| JP2019527194A5 (https=) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| JP2019532617A5 (https=) | ||
| EP2377555A3 (en) | Antibodies against vascular endothelial growth factor receptor-1 | |
| JP2017532952A5 (https=) | ||
| JP2019530428A5 (https=) | ||
| JP2011509245A5 (https=) | ||
| RU2018131123A (ru) | Антитела к tgf-бета2 | |
| JP2014519317A5 (https=) | ||
| JP2018509889A5 (https=) | ||
| JP2018522888A5 (https=) |